CB-103

• Background:

  Orally active inhibitor of the Notch signaling activation complex (IC50’s from 0.9 to 3.9 µM in various cell-based assays), the most downstream level of the Notch signaling pathway. It inhibited the growth of Notch-addicted human T cell acute lymphoblastic leukemia cells as well as other cell lines. CB-103 also inhibited the growth of human breast cancer and leukemia xenografts without the intestinal toxicity associated with γ-secretase Notch inhibitors.

• Conjugation:

  Unconjugated

• Buffer:

  Off-white to pale orange solid

• Storage Conditions:

  RT